The dry powder inhalation composition comprising(1) salmeterol xinafoate having mean particle size in range of 2.0μ-6μ microns and a tapped density in the range of 0.20 g·cm−3 to 0.45 g·cm−3 and(2) optionally, one or more other active ingredientsand pharmaceutically acceptable carrier.